Wyeth Foreign Growth Strong While Alavert Sales Pick Up At Home
This article was originally published in The Tan Sheet
Executive Summary
Sales for Wyeth's non-sedating antihistamine Alavert (loratadine) more than quadrupled compared to the previous quarter
You may also be interested in...
Sales & Earnings In Brief
Schering-Plough: Double-digit gains by OTC Claritin and sun care triggered a strong second quarter for the consumer health division, up 19% to $317 mil. Claritin sales jumped 22% to $117 mil. due to trade inventory adjustments in the year-ago quarter. Sun care revenue totaled $78 mil. (up 60%) as a result of the "timing of orders and shipments, coupled with favorable weather conditions," and foot care rose 7% to $89 mil. Schering has "good work underway" on new Coppertone and Dr. Scholl's extensions, CEO Fred Hassan tells analysts July 21. The solid consumer health results were more than offset by continuing struggles in Rx pharmaceuticals, spending on the FDA consent decree and restructuring costs. Consolidated sales fell 7% to $2.15 bil. and the firm reported a net loss of $65 mil...
Loratadine Private Labelers Gain On Branded Alternatives
Private label loratadine is making market share inroads against branded Claritin (Schering-Plough) and Alavert (Wyeth)
Wyeth Sees Alavert Sales Decline In Fourth Quarter Despite Good Year
Sales for Wyeth's Alavert (loratadine) totaled $81.6 mil. in 2003, its first full year on the market, following a significant drop in the fourth quarter